Schizophrenia May be Tied to Higher Risk of COVID-19 Death

Last Updated 29 January, 2021. Cellspect Co., Ltd.

On Oct. 22, the U.S. Food and Drug Administration (FDA) approved the Gilead‘s antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. The drug is the first approved treatment for COVID-19 and was also the drug that U.S. President Donald Trump received when he contracted the virus earlier this month. [1]


Remdesivir, which was originally developed as a treatment for Ebola and hepatitis C, interferes with the reproduction of viruses by jamming itself into new viral genes. Remdesivir had been authorized for use on an emergency basis since the spring. However, it now becomes the first drug to win full FDA approval for treating COVID-19. The approval of remdesivir was supported by the agency’s analysis of data from three randomized, controlled clinical trials that included patients hospitalized with mild-to-severe COVID-19. According to the trial data, remdesivir reduced patients' symptoms more quickly than standard care alone and significantly shortened patients' hospital stays, according to the statement. In one trial that included more than 1,000 patients, those who received the drug spent about five fewer days in the hospital than those who didn't. [2, 3]


However, despite being the first FDA-approved COVID-19 drug in the U.S., remdesivir isn't a highly effective treatment. A recent trial conducted by the World Health Organization (WHO) contradicts these positive findings. The trial, which included more than 11,200 people from 30 countries, found that remdesivir did not significantly reduce patients' time in the hospital, nor did it reduce the risk of being placed on a ventilator. And most importantly, the drug did not increase patients' chance of survival. [3] But the WHO trial has not yet been peer-reviewed, and it has drawn some critique from researchers such as the study did not include a placebo group and the trial took place at 405 different hospitals around the world where patients' care may have differed greatly. [4]


Its price has been controversial as well. Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. This seems to be an unaffordable price for many families.


On Oct. 25, the U.S. recorded its highest seven-day average of new COVID-19 cases since the start of the pandemic. The seven-day average number of new daily cases reached 68,767, breaking the previous record of 67,293 reported on July 22, according to CNN. On both Oct. 23 and Oct. 24, the U.S. recorded more than 83,000 new cases of COVID-19, the highest daily counts yet, shattering the records set in July. Hospitalizations are up 40 percent and deaths are creeping up in several states. France and several European countries have also come to a national lockdown again.[5] Apparently, Covid-19 is still raging in this world and we still have a long-term battle to fight against this virus.


  1. Katlyn Nemani et al. 27 Jan 2021. “Association of Psychiatric Disorders With Mortality Among Patients With COVID-19” JAMA Psychiatry.

  2. QuanQiu Wang et al. 7 Oct 2020. “Increased risk of COVID‐19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States” Would Psychiatry.

  3. Yasemin Saplakoglu. 27 Jan 2021. “Schizophrenia is 2nd highest risk factor for dying of COVID-19, after age” Live Science News

  4. Maxime Taquet et al. 9 Nov 2020. “Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA” The Lancet Psychiatry.

Regarding the information on this website (disclaimer):

The information on this website represents the best information currently available to us and is given in good faith but without warranty. We are not responsible for any loss caused by using this website. Please note that we may make changes to the information posted on this website without notice. In addition, the operation of the website may be suspended or stopped.